Jeanne Bolger (1)
[ July 25, 2024 by Ciara Brosnan 0 Comments ]

Jeanne Bolger

Jeanne has over 35 years of pharmaceutical industry experience in management roles across R&D, Commercial and Business Development (BD) and Venture Investments.  She spent 11 years in Licensing and Acquisition (L&A), including Global Head of Scientific Licensing for Johnson & Johnson’s Pharmaceutical business, and before that as Director in the Business Development group at GlaxoSmithKline.

Jeanne spent nearly 10 years (2012-2022) as Vice President Venture Investment in J&J’s corporate venture fund, Johnson & Johnson Innovation – JJDC. During that period, she was based in London, leading investments across Europe in start-up and early stage life science companies in areas of strategic interest to J&J’s business sectors in Pharmaceuticals and Biotechnology, Medical Devices and Consumer.  She represented JJDC on the Board of Directors of over a dozen companies, including Aelix Therapeutics, Asceneuron SA, Aviado Bio, Biocartis, Calypso Biotech, Inivata, Merus, Pulmocide, S-Biomedic, Syndesi, T-Rex.  Dr Bolger also represented JJDC’s LP investments in multiple Venture Capital Funds in UK and Europe as well as representing J&J’s interests in other funding vehicles including incubators and accelerators.

Screenshot 2024-07-23 at 15.42.20
[ July 25, 2024 by Ciara Brosnan 0 Comments ]

Niall O’Neill

Niall leads product, implementation, and customer success as well as strategic partnerships. Prior to Oneview, he was in management consulting including roles with Accenture and Deloitte.

Michael Suk
[ July 12, 2024 by Ciara Brosnan 0 Comments ]

Dr Michael Suk

Michael Suk, MD, JD, MPH, MBA, a board-certified orthopaedic surgeon who was first elected to the American Medical Association Board of Trustees in June 2019, became board chair in June 2024. Throughout his career, Dr. Suk has been a vocal leader on public health issues, including the role and importance of organized medicine, resident work hours, social determinants of health and numerous other public health concerns.

An active and engaged leader from his earliest days in organized medicine, Dr. Suk was the first medical student and first Asian-American elected to the AMA Board of Trustees in 1994. In addition, he has served on the AMA Council on Medical Service and as chair of the AMA Resident and Fellow Section where he led AMA efforts to create governance guidelines on resident work hours. In 2016, to help spearhead advocacy for the medical profession in Washington, D.C., Dr. Suk was appointed to the board of directors of the American Medical Political Action Committee. Additionally, reflecting his passion and expertise in the field of performance excellence, quality and safety, Dr. Suk was selected to the Board of Commissioners at the Joint Commission and currently serves as vice chair.

Dr. Suk is professor and chair of the Musculoskeletal Institute and the Department of Orthopaedic Surgery at the renowned Geisinger Health System based in Danville, Penn. Additionally, he serves as chief physician officer of Geisinger System Services, where he provides clinical leadership over the system’s $1.5B enterprise supply chain and pharmacy division.

Dr. Suk, who was selected as a White House Fellow under President George W. Bush in 2003 and as a Baldrige Executive Fellow in 2017, is widely sought after for his expertise in new models for health care payment and delivery, physician engagement, and leadership. In 2018, for example, he disrupted the dialogue on value-based care by developing and offering the world’s first “lifetime warranty” for total joint replacement. Dr. Suk is also one of the nation’s leading clinical voices for well-being through connections with nature, outdoor recreation and unstructured play.

He received a BA in African American history from Carleton College before simultaneously completing an MD at the University of Illinois College of Medicine and a JD/MPH with special certification in health care law at Boston University School of Law and School of Public Health. He later completed his orthopaedic surgery residency training at Montefiore Medical Center in Bronx, N.Y., and his fellowship in orthopaedic trauma at the Hospital for Special Surgery in New York City. In addition, Dr. Suk completed his MBA at the University of Scranton.

Mathias Goyen.
[ July 12, 2024 by Ciara Brosnan 0 Comments ]

Mathias Goyen

Paul Burton..
[ July 12, 2024 by Ciara Brosnan 0 Comments ]

Dr Paul Burton

Paul Burton, M.D., Ph.D., F.A.C.C., M.R.C.S., F.R.C.P., became Amgen’s Chief Medical Officer (CMO) in June 2023.

Burton had previous experience working for Amgen, as Global Development Leader from 2002 to 2005, following the company’s merger with Immunex. Prior to his return to Amgen, he was CMO of Moderna Therapeutics, with global responsibility for all medical strategy as well as patient safety and pharmacovigilance, from 2021 to 2023. Before that, he spent 16 years at Johnson & Johnson, where his last role was Chief Global Medical Affairs Officer.

Burton has more than 20 years of biopharmaceutical industry experience, across all phases of drug discovery and development, spanning small and large molecules as well as mRNA therapeutics. He has also worked across multiple therapeutic areas, including oncology, cardiovascular and metabolic disease, and infectious diseases.

Burton is a physician trained at University of London, in the United Kingdom. He received post graduate training in cardiovascular surgery, and he holds a PhD in molecular and cellular biology from Imperial College, London. He is a Member of the Royal College of Surgeons, a Fellow of the American College of Cardiology, an elected Fellow of the Royal College of Physicians, and has published extensively in clinical and digital medicine.

Eva Maria Hempe
[ July 12, 2024 by Ciara Brosnan 0 Comments ]

Eva-Maria Hempe

Eva-Maria, Head of Healthcare and Lifesciences EMEA at NVIDIA, brings over 15 years experience in healthcare, strategy, and innovation, having worked with the English NHS, the World Economic Forum, Bain & Company, and VMware. She is dedicated to developing AI-powered tools for healthcare, aiming to improve global health outcomes.

Eva-Maria holds a PhD in Engineering Design from the University of Cambridge and a master’s in Physics from the University of Regensburg.

John Sheehan Headshot
[ July 12, 2024 by Ciara Brosnan 0 Comments ]

Dr John Sheehan

John is a graduate of RCSI and qualified as a Radiologist in 2005. He did fellowships in MRI (Body, Neuro & MSK) & Cardiovascular Imaging in Northwestern Memorial Hospital, Chicago, 2006-2009 and was appointed Chief of Cardiovascular Imaging, NorthShore University Health System, Chicago in 200John currently practices as a Consultant Radiologist in Blackrock Health (Hermitage & Blackrock Clinic’s) and Mobile Medical Diagnostics. His practice includes Diagnostic & Interventional Radiology with cross-sectional interests in cardiovascular, hepato-biliary, prostate, MSK, and Colonography.

John is the Clinical Director of Radiology in the Hermitage Clinic, Clinical Director of Mobile Medical Diagnostics, and Clinical Advisor to xWave Technologies (xRefer)He has a passionate accumulated knowledge & experience in existing & emerging technologies in radiology & wider healthcare, including cloud, AI and Augmented Reality to help innovate & influence technology policy, by integrating clinical, digital, healthcare providers & industry realms.

John is a member of the Irish Digital Health Leadership Strategy Group (DHLSG) led by Prof. Martin Curley, comprised of leading digital health entrepreneurs, corporate leaders, clinicians, patients, academics & others. The charter of the group is to agree, align, and accelerate Ireland’s Digital Health Strategy & Action plan – Stay Left, Shift Left, 10x, enabling Ireland to leapfrog in digital health & overall health maturity. Core of the strategy is that digital technology provides an opportunity to provide 10x innovations or improvements, doing healthcare 10x better, faster, cheaper & increased capacity. The ultimate aim is to make Ireland a European leader in Healthcare by 2025 and a Global leader by 2030.

Screenshot 2024-07-10 at 18.52.50
[ July 12, 2024 by Ciara Brosnan 0 Comments ]

Gerry Walsh